A technological platform to combat cancer therapy resistance (Q4294205): Difference between revisions
Jump to navigation
Jump to search
(Created a new Item: Import item from Austria, Italy) |
(Changed label, description and/or aliases in en: Setting new description) |
||
| description / en | description / en | ||
Project Q4294205 in Austria, Italy | |||
Revision as of 15:05, 10 June 2022
Project Q4294205 in Austria, Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A technological platform to combat cancer therapy resistance |
Project Q4294205 in Austria, Italy |
Statements
589,335.6 Euro
0 references
838,556.0 Euro
0 references
70.28 percent
0 references
1 August 2019
0 references
31 January 2022
0 references
Universitá degli Studi di Trieste
0 references
47°15'42.01"N, 11°23'1.57"E
0 references
47°15'46.73"N, 11°23'3.91"E
0 references
46°29'56.65"N, 11°18'25.96"E
0 references
45°39'30.78"N, 13°47'35.66"E
0 references
The development of resistance to cancer therapy is one of the most frequent reasons for the failure of anti-cancer treatments. Therapy resistance is linked with tumor-recurrence and has devastating consequences for the clinical outcome of the individual patient and causes increased costs for public health systems. The understanding of mechanisms of resistance-formation and the development of strategies directed towards the resensitization of resistant tumor cells to cancer therapy represents one of the most important challenges to modern cancer research. P-CARE will strengthen the collaboration between Italian and Austrian research institutes in the areas of genetics, biotechnology and the cancer clinics and generate a technical platform to investigate mechanism of therapy resistance formation, aiming to increase the efficacy of therapeutic treatments. The project will develop a shared platform for the identification of drugs capable to re-sensitize resistant tumors to conventional oncologic treatments by the repositioning of drugs already approved for the treatment of other pathologies. Further, P-CARE will implement strategies of precision medicine aiming to overcome resistance to anti-cancer immunotherapy by reproducing the immune response of the tumormicorenviroment in vitro. P-CARE will build an efficient trans-border network for sharing technology and knowledge that will be made accessible for academic and clinical cancer research in and outside the Programme area. (English)
0 references